ArticleJournal of magnetic resonance imaging : JMRI2019
Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.
Article in Journal of magnetic resonance imaging : JMRI, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01564368 (Diffusion Weighted MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment), which is not on this map. Cited by 66 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Diffusion Weighted MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: A Sub-study of the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And MoLecular Analysis)
Who cites it
66 citing papers in PubMed, 3 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper.Frontiers in oncology · 2021Pooled it
- Diffusion-weighted imaging of the breast-a consensus and mission statement from the EUSOBI International Breast Diffusion-Weighted Imaging working group.European radiology · 2020Guideline
- Consensus-based technical recommendations for clinical translation of renal diffusion-weighted MRI.Magma (New York, N.Y.) · 2020Pooled it
- Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.Journal of magnetic resonance imaging : JMRI · 2019Trial
- Diffusion-weighted Imaging and ADC Mapping for Early Prediction of Pathologic Complete Response in Breast Cancer.Radiology. Imaging cancer · 2026Article
- Automated Apparent Diffusion Coefficient Measurement of Breast Tumors in Diffusion-weighted MRI for Early Neoadjuvant Chemotherapy Response Assessment.Radiology. Imaging cancer · 2026Article
- Image Quality Assessment of Diffusion-Weighted Imaging (DWI) and Its Impact on Apparent Diffusion Coefficient (ADC) as a Quantitative Imaging Biomarker for Predicting Response to Neoadjuvant Chemotherapy in High-Risk Early Breast Cancer.Tomography (Ann Arbor, Mich.) · 2026Article
- Enhancing Study Design and Analysis of MR Imaging Markers Through Measurement Error Modeling.Journal of magnetic resonance imaging : JMRI · 2026Article
- The role of diffusion-weighted MRI in biological image-guided radiation therapy: a roadmap.Physics in medicine and biology · 2026Review
- Apparent diffusion coefficient and intravoxel incoherent motion-derived true diffusion serve as early non-contrast longitudinal biomarkers of neoadjuvant chemotherapy response.Scientific reports · 2026Article
- Precision Diffusion-Weighted Imaging of Head and Neck Squamous Cell Carcinoma.AJNR. American journal of neuroradiology · 2026Article
- A multiparametric magnetic resonance imaging model incorporating the relative apparent diffusion coefficient for preoperative discrimination of triple-negative breast cancer.American journal of translational research · 2026Article
- Article
- Diagnostic performance of Kaiser score, ADC, and their combination for BI-RADS 4 breast lesions: subgroup and misclassification analysis.Frontiers in oncology · 2026Article
- Prediction of Early Neoadjuvant Chemotherapy Response of Breast Cancer through Deep Learning-based Pharmacokinetic Quantification of DCE MRI.Radiology. Artificial intelligence · 2025Article
- Evaluating Breast Cancer Intravoxel Incoherent Motion MRI Biomarkers across Software Platforms.Radiology. Imaging cancer · 2025Article
- Breast Diffusion-weighted MR Imaging: Current Applications, Insights from Screening, and Future Directions.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2025Review
- Fat-signal suppression in breast diffusion-weighted imaging: the Good, the Bad, and the Ugly.European radiology · 2025Article
- Comparison of intensity normalization methods in prostate, brain, and breast cancer multi-parametric magnetic resonance imaging.Frontiers in oncology · 2025Article
- Optimized Synthetic Correlated Diffusion Imaging for Improving Breast Cancer Tumor Delineation.Sensors (Basel, Switzerland) · 2024Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 15 institutions in 1 country.
Funding
Abstract
backgroundQuantitative diffusion-weighted imaging (DWI) MRI is a promising technique for cancer characterization and treatment monitoring. Knowledge of the reproducibility of DWI metrics in breast tumors is necessary to apply DWI as a clinical biomarker. PURPOSE: To evaluate the repeatability and reproducibility of breast tumor apparent diffusion coefficient (ADC) in a multi-institution clinical trial setting, using standardized DWI protocols and quality assurance (QA) procedures. STUDY TYPE: Prospective. SUBJECTS: In all, 89 women from nine institutions undergoing neoadjuvant chemotherapy for invasive breast cancer. FIELD STRENGTH/SEQUENCE: DWI was acquired before and after patient repositioning using a four b-value, single-shot echo-planar sequence at 1.5T or 3.0T. ASSESSMENT: A QA procedure by trained operators assessed artifacts, fat suppression, and signal-to-noise ratio, and determine study analyzability. Mean tumor ADC was measured via manual segmentation of the multislice tumor region referencing DWI and contrast-enhanced images. Twenty cases were evaluated multiple times to assess intra- and interoperator variability. Segmentation similarity was assessed via the Sørenson-Dice similarity coefficient. STATISTICAL TESTS: Repeatability and reproducibility were evaluated using within-subject coefficient of variation (wCV), intraclass correlation coefficient (ICC), agreement index (AI), and repeatability coefficient (RC). Correlations were measured by Pearson's correlation coefficients.
resultsIn all, 71 cases (80%) passed QA evaluation: 44 at 1.5T, 27 at 3.0T; 60 pretreatment, 11 after 3 weeks of taxane-based treatment. ADC repeatability was excellent: wCV = 4.8% (95% confidence interval [CI] 4.0, 5.7%), ICC = 0.97 (95% CI 0.95, 0.98), AI = 0.83 (95% CI 0.76, 0.87), and RC = 0.16 * 10 DATA
conclusionBreast tumor ADC can be measured with excellent repeatability and reproducibility in a multi-institution setting using a standardized protocol and QA procedure. Improvements to DWI image quality could reduce loss of data in clinical trials. LEVEL OF EVIDENCE: 2 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2019;49:1617-1628.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.